| AD | Alzheimer’s disease |
| ALS | Amyotrophic lateral sclerosis |
| ASD | Autism spectrum disorders |
| ATP5A | ATP synthase alpha-subunit |
| ATPB | ATP synthase beta-subunit |
| CD9 | Cluster of Differentiation 9 |
| CD81 | Cluster of Differentiation 81 |
| COX | Cytochrome c oxidase subunit |
| ΔΔCT | Delta cycle threshold |
| DIV | Days in vitro |
| EVs | Extracellular vesicles |
| FMRP | Fragile X mental retardation protein |
| Fmr1 KO | Fmr1 knockout (Fmr1-/y) |
| FXS | Fragile X syndrome |
| GFAP | Glial fibrillary acidic protein |
| JC-1 | Tetraethyl benzimidazolyl carbocyanine iodide |
| LC/MS | Liquid chromatography-mass spectrometry |
| MMP | Mitochondrial membrane potential |
| MT-CO1 | COX subunit I encoded by mitochondrial DNA |
| mtTFA | Mitochondrial transcription factor A |
| NTA | Nanoparticle tracking analysis |
| NRF-1 | Nuclear factor, erythroid derived 2, like 1 |
| NRF-2 | Nuclear factor, erythroid derived 2, like 2 |
| P2 | Postnatal days 2 |
| PBS | Phosphate buffered saline |
| PD | Parkinson’s disease |
| PINK1 | PTEN-induced kinase 1 |
| RPLP0 | Nuclear gene ribosomal protein large p0 |
| TEM | Transmission electron microscopy |
| VDAC1 | Voltage-dependent anion-selective channel 1 |
| VIF | Vimentin intermediate filament |
| WT | Wild-type (Fmr1+/y) |